Interleukin-10-induced T cell unresponsiveness can be reversed by dendritic cell stimulation

被引:16
作者
Chen, ML [1 ]
Wang, FH [1 ]
Lee, PK [1 ]
Lin, CM [1 ]
机构
[1] Soochow Univ, Dept Microbiol, Taipei 11102, Taiwan
关键词
immunotherapy; dendritic cell; interleukin-10;
D O I
10.1016/S0165-2478(00)00301-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The secretion of immunosuppressive factors like interleukin-10 (IL-10), either by tumor cells or by tumor-infiltrating leukocytes, has been recognized as one of the mechanisms involved in tumor immunological escape and a serious obstacle for successful immunotherapy. Therefore, any therapeutic attempts aimed at inducing antitumor immunity in tumor-bearing hosts must overcome this immunosuppressive state. This study aimed to determine whether dendritic cell (DC) immunization, a promising approach to induce antitumor immunity, could break IL-10-induced anergic state in CD4(+) T cells, essential cells in generating tumor-specific immunity. We found that the ability of DC to reverse IL-10-induced anergic state in human CD4(+) T cells is dependent on the IL-10 concentration that T cells have been exposed to and the degree of DC maturation. The efficacy of mature DC in reversing T cell anergy can be mimicked by higher cell numbers of immature DC. In addition, activated T cells induced by DC stimulation are sensitive to IL-10 treatment. Collectively, our results, suggest the use of mature DC and the necessity of antagonizing the action of tumor-derived IL-10 in immunotherapy of cancer with DC immunization. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 23 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]   The host-tumor immune conflict: from immunosuppression to resistance and destruction [J].
Chouaib, S ;
AsselinPaturel, C ;
MamiChouaib, F ;
Caignard, A ;
Blay, JY .
IMMUNOLOGY TODAY, 1997, 18 (10) :493-497
[3]   Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [J].
Gabrilovich, DI ;
Chen, HL ;
Cunningham, HT ;
Meny, GM ;
Nadaf, S ;
Kavanaugh, D ;
Carbone, DP .
NATURE MEDICINE, 1996, 2 (10) :1096-1103
[4]   INTERLEUKIN-10 PRODUCTION BY HUMAN CARCINOMA CELL-LINES AND ITS RELATIONSHIP TO INTERLEUKIN-6 EXPRESSION [J].
GASTL, GA ;
ABRAMS, JS ;
NANUS, DM ;
OOSTERKAMP, R ;
SILVER, J ;
LIU, F ;
CHEN, M ;
ALBINO, AP ;
BANDER, NH .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (01) :96-101
[5]   Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells [J].
Gong, JL ;
Chen, DS ;
Kashiwaba, M ;
Li, YQ ;
Chen, L ;
Takeuchi, H ;
Qu, H ;
Rowse, GJ ;
Gendler, SJ ;
Kufe, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6279-6283
[6]   DENDRITIC CELLS AS INITIATORS OF TUMOR IMMUNE-RESPONSES - A POSSIBLE STRATEGY FOR TUMOR-IMMUNOTHERAPY [J].
GRABBE, S ;
BEISSERT, S ;
SCHWARZ, T ;
GRANSTEIN, RD .
IMMUNOLOGY TODAY, 1995, 16 (03) :117-121
[7]   Interleukin-10 induces a long-term antigen-specific anergic state in human CD4(+) T cells [J].
Groux, H ;
Bigler, M ;
deVries, JE ;
Roncarolo, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :19-29
[8]   Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells [J].
Hsu, FJ ;
Benike, C ;
Fagnoni, F ;
Liles, TM ;
Czerwinski, D ;
Taidi, B ;
Engleman, EG ;
Levy, R .
NATURE MEDICINE, 1996, 2 (01) :52-58
[9]  
Labeur MS, 1999, J IMMUNOL, V162, P168
[10]   BONE-MARROW-DERIVED DENDRITIC CELLS PULSED WITH SYNTHETIC TUMOR PEPTIDES ELICIT PROTECTIVE AND THERAPEUTIC ANTITUMOR IMMUNITY [J].
MAYORDOMO, JI ;
ZORINA, T ;
STORKUS, WJ ;
ZITVOGEL, L ;
CELLUZZI, C ;
FALO, LD ;
MELIEF, CJ ;
ILDSTAD, ST ;
KAST, WM ;
DELEO, AB ;
LOTZE, MT .
NATURE MEDICINE, 1995, 1 (12) :1297-1302